This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Conjunctivitis, Allergic
and you are
over 10
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

Provided treatments

  • Drug: Alcaftadine 0.25%
  • Drug: Olopatadine 0.2%
  • Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Tris trial is registered with FDA with number: NCT01732757. The sponsor of the trial is Allergan and it is looking for 157 volunteers for the current phase.
Official trial title: